Publication list Johanna A. Kremer Hovinga

- ORCID ID 0000-0002-1300-7135
- Link to publications in pubmed (descending order): Johanna A. Kremer Hovinga in PubMed

1.) Publications in peer-reviewed journals

1	**Kremer Hovinga J**, Felix R, Furlan M, Lämmle B. Malondialdehyde formation by blood platelets: a diagnostic test to assess acetylsalicylic acid induced thrombocytopathy? *Thromb Res* **1990**;59:89-95
2	**Kremer Hovinga J**, Schaller J, Stricker H, Wuillemin WA, Furlan M, Lämmle B. Coagulation factor XII Locarno: The functional defect is caused by the amino acid substitution Arg 353 -> Pro leading to loss of the kallikrein cleavage site. *BLOOD* **1994**;84:1173-1181
3	Bühler R, **Kremer Hovinga J**, Aebi-Huber I, Furlan M, Lämmle B. Improved detection of proteolytically cleaved high molecular weight kininogen by immunoblotting using an antiserum against its reduced 47kDa light chain. *Blood Coagul Fibrinolysis* **1995**;6:223-232
4	Rieben R, Korchagina EY, von Allmen E, **Kremer Hovinga J**, Lämmle B, Jungi TW, Bovin NV, Nydegger UE. In vitro evaluation of the efficacy and biocompatibility of new, synthetic ABO immunoabsorbents. *Transplantation* **1995**;60:425-430
5	**Kremer Hovinga JA**, Wuillemin WA. Rezidivierende Hepatitis unter oraler Antikoagulation: Coumarin-induzierte Hepatitis. *Therap Umschau* **1999**;56:513-515
6	**Kremer Hovinga JA**, Baerlocher GM, Wuillemin WA, Solenthaler M. Tiefe Beinvenenthrombose bei erworbener Thrombophilie: Hyperhomozysteinämie als Folge einer nicht bekannten Zöliakie. *Therap Umschau* **1999**;56:519-522
7	Fontana S, Gerritsen HE, **Kremer Hovinga J**, Furlan M, Lämmle B. Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor- cleaving protease. *Br J Haematol* **2001**;113:100-102
8	Merlo C, Wuillemin WA, Redondo M, Furlan M, Sulzer I, **Kremer Hovinga J**, Binder BR, Lämmle B. Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease. *Atherosclerosis* **2002**;161:261-7
9 Not in pub med	**Kremer Hovinga JA (as J Kramer)**, Otten HM, Levi MM, ten Cate H. The association of disseminated intravascular coagulation with specific diseases. *Réanimation* **2002**;11:575-583
10	Demarmels Biasiutti F, **Kremer Hovinga Strebel J**. Antikoagulation und Antiaggregation in der Schwangerschaft. *Therap. Umschau* **2003**;60:54-58
11	Studt JD°, **Kremer Hovinga JA**°, Alberio L, Bianchi V, Lämmle B. Von Willebrand factor-cleaving protease (ADAMTS-13) activity in thrombotic microangiopathies: Diagnostic experience 2001/2002 of a single research laboratory. *Swiss Medical Weekly* **2003**;133:325-332 (°equal contribution)
12	Studt JD, **Kremer Hovinga JA**, Furlan M, Lämmle B. Discrepant activity levels of von Willebrand factor-cleaving protease (ADAMTS-13) in congenital thrombotic thrombocytopenic purpura. *BLOOD* **2003**;102:1148

13	Winkler A, **Kremer Hovinga JA**, Bianchi V, Studt JD, Lämmle B. Schistocytic anemia, severe thrombocytopenia and renal dysfunction: thrombotic microangiopathy due to severe acquired ADAMTS-13 deficiency. *Haemostaseologie* **2003**;3:103-108
14	**Kremer Hovinga JA**°, Studt JD, Lämmle B. The von Willebrand factor-cleaving protease (ADAMTS-13) and the diagnosis of thrombotic thrombocytopenic purpura (TTP). *Pathophysiology of Haemostasis and Thrombosis* **2003**;33(5-6):417-421 (°corresponding author)
15	**Kremer Hovinga JA**, Solenthaler M, Dufour JF. Congenital dyserythropoietic anaemia type II (HEMPAS) and haemochromatosis: A report of two cases. *Eur J Gastro Hepatol* **2003**;15:1141-1147
16 Not in pub med	Lämmle B, **Kremer Hovinga JA**, Studt JD, Alberio L. Forum: Deficiency of ADAMTS-13 in thrombotic and thrombocytopenic purpura. *J Thromb Haemostas* **2003**;1:2042-2044
17	**Kremer Hovinga JA**, Franco RF, Zago MA, ten Cate H, Westendorp RGJ, Reitsma PH. A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease. *J Thromb Haemostas* **2004**;2:54-57
18	Gerdes VEA, **Kremer Hovinga JA**, ten Cate H, Brandjes DPM, Büller HR on behalf of the Amsterdam Vascular Medicine Group. Soluble thrombomodulin in patients with established atherosclerosis. *J Thromb Haemostas* **2004**;2:200-201
19	Fontana S, **Kremer Hovinga JA**, Studt JD, Alberio L, Lämmle B, Mansouri Taleghani B. Plasma therapy in thrombotic thrombocytopenic purpura: Review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency. *Semin Hematol* **2004**;41:48-59
20	**Kremer Hovinga JA**, Studt JD, Alberio L, Lämmle B. Von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: The Swiss experience. *Semin Hematol* **2004**;41:75-82
21	Lämmle B, **Kremer Hovinga J**, Studt JD, Mansouri Taleghani B, Alberio L. Thrombotic thrombocytopenic purpura. *The Hematology Journal* **2004**;5:S6-S11
22	Gerdes VEA, **Kremer Hovinga HA**, ten Cate H, MacGillavry MR, Leijte A, Reitsma PH, Brandjes DPM, Büller HR on behalf of the Amsterdam Vascular Medicine Group. Homocysteine and markers of coagulation and endothelial cell activation. *J Thromb Haemost* **2004**;2:445-451
23	**Kremer Hovinga JA**, Studt JD, Demarmels Biasiutti F, Solenthaler M, Alberio L, Zwicky C, Fontana S, Mansouri Taleghani B, Tobler A, Lämmle B. Splenectomy in relapsing and plasma- refractory acquired thrombotic thrombocytopenic purpura. *Haematologica* **2004**;89:320-324
24	Studt JD, **Kremer Hovinga JA**, Radonic R, Gasparovic V, Ivanovic D, Merkler M, Wirthmueller U, Dahinden C, Furlan M, Lämmle B. Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins. *BLOOD* **2004**;103:4195-4197
25	Studt JD°, **Kremer Hovinga JA**°, Antoine G, Hermann M, Rieger M, Scheiflinger F, Lämmle B. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in-vitro inhibition of ADAMTS13 activity by hemoglobin. *BLOOD* **2005**;105:542-544 (°equal contribution)

26	Rittersma SZH, **Kremer Hovinga JA**, Koch KT, Boekholt SM, van Aken BE, Scheepmaker A, Bax M, Schotborgh CE, Piek JJ, Tijssen JGP, Reitsma PH, de Winter RJ. Relationship between in vitro lipopolysaccharide-induced cytokine response in whole blood, angiographic in-stent restenosis and Toll-like receptor 4 gene polymorphisms. *Clin Chem* **2005**;51:516-521
27	Terrell DR, Williams LA, Vesely SK, Lämmle B, **Kremer Hovinga JA**, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. *J Thromb Haemost* **2005**;3:1432-1436
28	Lämmle B, **Kremer Hovinga JA**, Alberio L. Thrombotic thrombocytopenic purpura. *J Thromb Haemostas* **2005**;3:1663-1675.
29	Rieger M, Mannucci PM, **Kremer Hovinga JA**, Herzog A, Gerstenbauer G, Konetschny C, Zimmermann K, Scharrer I, Peyvandi F, Galbusera M, Remuzzi G, Böhm M, Plaimauer B, Lämmle B, Scheiflinger F. ADAMTS13 autoantibodies in patients with thrombotic microangio-pathies and other immunomediated diseases. *BLOOD* **2005**;106:1262-1267
30	Krieg S, Studt JD, Sulzer I, Lämmle B, **Kremer Hovinga JA**. Is factor V Leiden a risk factor for thrombotic microangiopathies without severe ADAMTS13 deficiency? *Thromb Haemost* **2005**;94:1186-1189
31	Rieger M, Ferrari S, **Kremer Hovinga JA**, Konetschny C, Herzog A, Koller L, Weber A, Remuzzi G, Dockal M, Plaimauer B, Scheiflinger F. Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathy (TMA). *Thromb Haemost* **2006**;95:212-220
32	Fontana S, **Kremer Hovinga JA**, Lämmle B; Mansouri Taleghani B. Treatment of thrombotic thrombocytopenic purpura. *Vox Sanguinis* **2006**;90:245-254
33	Lämmle B, **Kremer Hovinga JA**. A new tool to further explore the role of ADAMTS-13 in health and disease. *J Thromb Haemostas* **2006**;4:952–954
34	**Kremer Hovinga JA**°, Mottini M, Lämmle B. Measurement of ADAMTS13 activity in plasma by the FRETS-VWF73 assay: Comparison with other assay methods. *J Thromb Haemostas* **2006**;4:1146-1148 (°corresponding author)
35	Schnog JB°, **Kremer Hovinga JA**°, Krieg S, Akin S, Lämmle B, Brandjes DPM, MacGillavry MR, Muskiet FD, Duits AJ on behalf of the CURAMA study group. ADAMTS13 activity in sickle cell disease. *Am J Hematol* **2006**;81:492-498 (°equal contribution)
36	Schneppenheim R, **Kremer Hovinga JA**, Becker T, Budde U, Karpman D, Brockhaus W, Hrachovinova, I, Korczowski B, Oyen F, Rittich S, von Rosen J, Tjønnfjord GE, Pimanda JE, Wienker TF, Lämmle B. A common origin of the 4143insA ADAMTS13 mutation. *Thromb Haemost* **2006**;96:3-6
37	Luken BM, Kaijen PHP, Turenhout EAM, **Kremer Hovinga JA**, van Mourik JA, Fijnheer R, Voorberg J. Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura. *J Thromb Haemostas* **2006**;4:2355-2364
38	Meyer SC, Sulzer I, Lämmle B, **Kremer Hovinga JA**. Hyperbilirubinemia interferes with ADAMTS13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. *J Thromb Haemostas* **2007**;5:866-867
39	Swisher KK, Doan JT, Vesely SK, Kwaan HC, Kim B, Lämmle B, **Kremer Hovinga JA**, George JN. Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. *Haematologica* **2007**;92:936-943

40	Rüfer A, Brodmann D, Gregor M, **Kremer Hovinga JA**, Lämmle B, Wuillemin WA. Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura - a case report and concise review of the literature. *Swiss Medical Weekly* **2007**;137:518-524
41	**Kremer Hovinga JA**°, Zeerleder S, Kessler P, Romani de Wit T, Van Mourik JA, Hack CE, Ten Cate H, Reitsma PH, Wuillemin WA, Lämmle B. ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. *J Thromb Haemost* **2007**;5:2284-2290 (°corresponding author)
42	Lämmle B, **Kremer Hovinga JA**, George JN. Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease. *Haematologica* **2008**;93:172-177
43	George JN, **Kremer Hovinga JA**, Terrell DR, Vesely SK, Lämmle B. The Oklahoma thrombotic thrombocytopenic purpura - hemolytic uremic syndrome registry: The Swiss connection. *Eur J Haematol*. **2008**;80:277-286
44	Karpac CA, Li X, Terrell DR, **Kremer Hovinga JA**, Lämmle B, Vesely SK, George JN. Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison. *Br J Haematol* **2008**;141:696-707
45	Meyer SC, Jeddi R, Meddeb B, Gouider E, Lämmle B, **Kremer Hovinga JA**. A first case of congenital TTP on the African continent due to a new homozygous mutation in the catalytic domain of ADAMTS13. *Annals of Hematology* **2008**;87:663-666
46	Tripodi A, Peyvandi F, Chantarangkul V, Palla R, Afrasiabi A, Canciani MT, Chung DW, Ferrari S, Fujimura Y, Karimi M, Kokame K, **Kremer Hovinga JA**, Lämmle B, De Meyer SF, Plaimauer B, Vanhoorelbeke K, Varadi K, Mannucci PM. Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). *J Thromb Haemost* **2008**;6:1534-1541
47	**Kremer Hovinga JA**, Meyer SC. Current management of thrombotic thrombocytopenic purpura. *Curr Opin Haematol* **2008**;15:445-450
48	Bergmann IP, **Kremer Hovinga JA**, Lämmle B, Peter HJ, Schiemann U. Acute pancreatitis and thrombotic thrombocytopenic purpura. *Eur J Med Res* **2008**;13:481-482
49	Pos W, Luken BM, **Kremer Hovinga JA**, Turenhout EAM, Scheiflinger F, Dong JF, Fijnheer R, Voorberg J. VH1-69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. *J Thromb Haemostas* **2009**;7:421-428
50	Benjamin M, Terrell DR, Vesely SK, Voskuhl GW, Dezube BJ, **Kremer Hovinga JA**, Lämmle B, George JN. Frequency and significance of HIV infection among patients diagnosed with thrombotic thrombocytopenic purpura. *Clin Infect Dis* **2009**;48:1129-1137
51	Swisher KK, Terrell DR, Vesely SK, **Kremer Hovinga JA**, Lämmle B, George JN. Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. *Transfusion* **2009**;49:873-887
52	Kennedy AS, Lewis QF, Scott JG, **Kremer Hovinga JA**, Lämmle B, Terrell DR, Vesely SK, George JN. Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. *Transfusion* **2009**;49:1092-1101
53	Ferrari S, Mudde GC, Rieger M, Veyradier A, **Kremer Hovinga JA**, Scheiflinger F. IgG-subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. *J Thromb Haemostas* **2009**;7:1703-1710
54	**Kremer Hovinga JA**, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. *BLOOD* **2010**;115:1500-1511

55	Terrell DR, Vesely SK, **Kremer Hovinga JA**, Lämmle B, George JN. Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. *Am J Hematol* **2010**;85:844-847
56	Plaimauer B, **Kremer Hovinga JA**, Juno C, Wolfsegger MJ, Skalicky S, Schmidt M, Grillberger L, Hasslacher M, Knöbl P, Ehrlich H, Scheiflinger F. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. *J Thromb Haemost* **2011**;9:936–944
57	Pos W, Luken BM, Sorvillo N, **Kremer Hovinga JA**, Voorberg J. Humoral immune response to ADAMTS13 in acquired thrombotic thrombocytopenic purpura. *J Thromb Haemostas* **2011**;9:1285–1291
58	Jahns M, Friess D, Demarmels Biasiutti F, **Kremer Hovinga JA**, Alberio L, Oldenburg J, Lämmle B, Colucci G. Massive muscle haematoma three months after starting vitamin K antagonist therapy for deep vein thrombosis in an antithrombin deficient patient: Another case of Factor IX propeptide mutation. *Thromb Haemostas* **2011**;106:381-382
59	Terrell DR, Motto DG, **Kremer Hovinga JA**, Lämmle B, George JN, Vesely SK. Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency. *Transfusion* **2011**; 51:2237-2243
60	**Kremer Hovinga JA**, Lämmle B. Role of ADAMTS13 in the pathogenesis, diagnosis and treatment of thrombotic thrombocytopenic purpura. *Hematology Am Soc Hematol Educ Program* **2012**;2012:610-616
61	Fröhlich-Zahnd R, George JN, Vesely SK, Terrell DR, Aboulfatova K, Dong JF, Luken BM, Voorberg J, Budde U, Sulzer I, Lämmle B, **Kremer Hovinga JA**. Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. *Haematologica* **2012**;97:297-303
62	George JN, Terrell DR, Vesely SK, **Kremer Hovinga JA**, Lämmle B. Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer. *Presse Medicale* **2012**;41:e177-e188
63	Cataland S, Peyvandi F, Mannucci PM, Lämmle B, **Kremer Hovinga JA**, Machin SJ, Scully S, Rock G, Gilbert JC, Yang S, Wu H, Jilma B, Knöbl P. Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. *Am J Hematol* **2012**;87:430-432
64	**Kremer Hovinga JA,** Voorberg J. Improving on nature, re-designing ADAMTS13. *BLOOD* **2012**;119:3654-3655
65	Fuchs TA, **Kremer Hovinga JA**, Schatzberg D, Wagner DD, Lämmle B. Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. *BLOOD* **2012**;120:1157-1164
66	Du VX, van Os G, **Kremer Hovinga JA**, Dienava-Verdoold I, Wollersheim J, Ruggeri ZM, Fijnheer R, de Groot PG, de Laat B. Indications for a protective function of beta2-glycoprotein I in thrombotic thrombocytopenic purpura. *Br J Haematol* **2012**;159:94–103
67	Som S, Deford CC, Kaiser ML, Terrell DR, **Kremer Hovinga JA**, Lämmle B, George JN, Vesely SK. Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura - hemolytic uremic syndrome, 1996-2011. *Transfusion* **2012**;52:2525-2532
68	Hausammann S, Vogel M, **Kremer Hovinga JA**, Lacroix-Desmazes S, Stadler BM, Horn MP. Designed Ankyrin Repeat Proteins: a new approach to mimic complex antigens for diagnostic purposes? *PLoS One* **2013**;8:e60688

69	**Kremer Hovinga JA.** Thrombotic microangiopathies. *Haemostaseologie* **2013**;33:81
70	Mansouri Taleghani M, von Krogh A-S, Fujimura Y, George JN, Hrachovinova I, Knöbl PN, Quist-Paulsen P, Schneppenheim R, Lämmle B, **Kremer Hovinga JA**. Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman syndrome) and the hereditary TTP registry. *Haemostaseologie* **2013**;33:138–143
71	Schaller M, Studt JD, Voorberg J, **Kremer Hovinga JA**. Acquired thrombotic thrombocytopenic purpura. Development of an autoimmune response. *Haemostaseologie* **2013**;33:121–130
72	Deal T, **Kremer Hovinga JA**, Marques MB, Adamski J. Novel *ADAMTS13* Mutations in an Obstetric Patient with Upshaw-Schulman Syndrome. *J Clin Apheresis* **2013**;28:311-316
73	Deford CC, Reese JA, Schwartz LH, Perdue JJ, **Kremer Hovinga JA**, Lämmle B, Terrell DR, Vesely SK, George JN. Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. *BLOOD* **2013**;122:2023-9
74	Diaz JA, Fuchs TA, Jackson TO, **Kremer Hovinga JA**, Lämmle B, Henke PK, Myers Jr. DD, Wagner DD, Wakefield TW. Plasma DNA is Elevated in Patients with Deep Vein Thrombosis. *Journal of Vascular Surgery: Venous and Lymphatic Disorders* **2013**;1:341-348.e1
75	Reese JA, Muthurajah DS, **Kremer Hovinga JA**, Vesely SK, Terrell DR, George JN. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired ADAMTS13 deficiency: comparison of incidence, demographic and clinical features. *Pediatr Blood Cancer* **2013**;60:1676-82
76	Rank CU, **Kremer Hovinga JA**, Taleghani MM, Lämmle B, Gøtze JP, Nielsen OJ. Congenital thrombotic thrombocytopenic purpura caused by new compound heterozygous mutations of the ADAMTS13 gene. *Eur J Haematol*. **2013**; 92:168-71
77	Jiang Y, McIntosh JJ, Reese JA, Deford CC, **Kremer Hovinga JA**, Lämmle B, Terrell DR, Vesely SK, Knudtson EJ, George JN. Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. *BLOOD* **2014**;123:1674-80
78	Ferrari S, Palavra K, Gruber B, **Kremer Hovinga JA**, Knöbl P, Caron C, Cromwell C, Aledort L, Plaimauer B, Turecek PL, Rottensteiner H, Scheiflinger F. Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura. *Haematologica* **2014**;99:779-87
79	Von Krogh A-S, **Kremer Hovinga JA**, Tjønnfjord GE, Ringen IM, Lämmle B, Waage A, Quist-Paulsen P. The impact of congenital thrombotic thrombocytopenic purpura on pregnancy complications. *Thromb Haemost* **2014**;111:1180–1183
80	Falter T, **Kremer Hovinga JA**, Lackner K, Füllemann H-G, Lämmle B, Scharrer I. Late onset and pregnancy-induced congenital thrombotic thrombocytopenic purpura. *Haemostaseologie* **2014**;34:244–24
81	Adler M**, Kremer Hovinga JA**, Lämmle B. Le purpura thrombotique thrombocytopénique – un diagnostic méconnu. *Rev Med Suisse* **2014**;10:2280-2284
82	Schaller M, Vogel M, Kentouche K, Lämmle B, **Kremer Hovinga JA**. The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR3 motifs. *BLOOD* **2014**;124:3469-3479
83	Raval JS, Padmanabhan A, **Kremer Hovinga JA**, Kiss JE. Development of a clinically significant ADAMTS13 inhibitor in a patient with hereditary thrombotic thrombocytopenic purpura. *Am J Hematol* **2015**;90(1):E22

84	Von Auer C, von Krogh A-S, **Kremer Hovinga JA**, Lämmle B. Current insights into thrombotic microangiopathies: Thrombotic thrombocytopenic purpura and pregnancy. *Thromb Res* **2015**; 135 (Suppl. 1):S30–S33
85	Edgar CE, Terrell DR, Vesely SK, Dizmorov IM, Wren JD, Niewold TB, Brown M, Zhou F, Frank MB, Merrill JT, **Kremer Hovinga JA**, Lämmle B, James JA; George JN, Farris AD. Ribosomal and immune transcripts associate with relapse in ADAMTS13-deficient thrombotic thrombocytopenic purpura. *PLOS ONE* **2015**;10(2):e0117614
86	Jimenez-Alcazar M, Napirei M, Panda R, Kohler EC, **Kremer Hovinga JA**, Mannherz HG, Peine S, Renne T, Lämmle B, Fuchs TA. Impaired DNase1-mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies. *J Thromb Haemost* **2015**;13:732–42
87	Arni D, Gumy-Pause F, Ansari M, **Kremer Hovinga JA**, McLin VA. Successful liver transplantation in a child with acute-on-chronic liver failure and acquired thrombotic thrombocytopenic purpura. *Liver Transplantation* **2015**;21:704-706
88	Hubbard AR, Heath AB, **Kremer Hovinga JA**. Establishment of the WHO 1st International Standard ADAMTS13, plasma (12/252). *J Thromb Haemost* **2015**;13:1151-3
89	Von Krogh A-S, **Kremer Hovinga JA**, Romundstad PR, Roten LT, Lämmle B, Waage A, Quist-Paulsen P. ADAMTS13 gene variants and function in women with preeclampsia: a population- based nested case- control study from the HUNT study. *Thromb Res* **2015**;136: 282-8
90 Not in pub med	**Kremer Hovinga JA**. SCHLAGLICHT HÄMATOLOGIE 2015: 111 Jahre nach Alexei Nikolajewitsch Romanow – Heilung für schwere Hämophilie B in Sicht. *Swiss Med Forum* **2016**;1:9-11 **Kremer Hovinga JA**. HIGHLIGHTS HÉMATOLOGIE 2015: 111 années après Alexis Nikolaïevitch Romanov, guérison de l'hémophilie B sévère en perspective. *Swiss Med Forum* **2016**;1:9-11
91	Von Krogh A-S, Quist-Paulsen P, Waage A, Langseth ØO, Throstensen K, Brudevold R, Tjønnfjord GE, Largiadèr CR, Lämmle B, **Kremer Hovinga JA**. High prevalence of hereditary thrombotic thrombocytopenic purpura in Central Norway: from clinical observation to evidence. *J Thromb Haemost* **2016**;14:73-82
92	Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ; EHA Roadmap for European Hematology Research (284 collaborators, including **J. Kremer Hovinga**). The European Hematology Association Roadmap for European Hematology Research: a consensus document. *Haematologica* **2016**;101:115-208
93	Peyvandi F, Scully M, **Kremer Hovinga JA**, Cataland S, Knöbl P, Wu H, Artoni A, Westwood J-P, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D, for the TITAN investigators. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. *N Engl J Med* **2016**;374:511-22
94	Fan X, **Kremer Hovinga JA**°, Shirotani-Ikejima H, Eura Y, Hirai H, Honda S, Kokame K, Mansouri Taleghani M, Von Krogh A-S, Yoshida Y, Fujimura Y, Lämmle B, Miyata T. Genetic variations in complement factors in patients with congenital thrombotic thrombocytopenic purpura with renal insufficiency. *Int J Hematol* **2016**;103:283–291 (°corresponding author)
95	Pedrazzini G, Biasco L, Anesini A, Sulzer I, **Kremer Hovinga JA**, Alberio L. Acquired intracoronary ADAMTS13 deficiency and von Willebrand factor retention at sites of critical coronary stenosis in patients with STEMI. *BLOOD* **2016**;127:2934-6

96	Page EE, **Kremer Hovinga JA**, Terrell DR, Vesely SK, George JN. Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. *BLOOD* **2016**;127:3092-3094
97	Pavenski K, Cataland S, **Kremer Hovinga J**, Thomas M, Vanhoorelbeke K. Thrombotic thrombocytopenic purpura (TTP) Dinner Symposium Proceedings. *Expert Rev Hematol* **2016**;9:733-5
98	Nagler M, **Kremer Hovinga JA**°, Alberio L, Peter-Salonen K, von Tengg-Kobligk H, Lottaz D; Neerman-Arbez M, Lämmle B. Thromboembolism in patients with congenital afibrinogenemia – long-term observational data and systematic review. *Thromb Haemost* **2016**;116:722-32 (°corresponding author)
99	Page EE, **Kremer Hovinga JA**, Terrell DR, Vesely SK, George JN. Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura. *BLOOD* **2016**;128:2175-2178
100	Kölm R, Schaller M, Roumenina LT, Niemiec I, **Kremer Hovinga JA**, Khanicheh E; Kaufmann BA, Hopfer H, Trendelenburg M. Von Willebrand factor interacts with surface-bound C1q and induces platelet rolling. *J Immunol* **2016**;197:3669-3679
101 Not in pub med	**Kremer Hovinga JA**. 61st Annual Meeting of the Gesellschaft für Thrombose und Hämostaseforschung e.V. From individual patients to pathophysiological insights. *Haemostaseologie* **2017**;37:5-7
102	**Kremer Hovinga JA**, Scharf RE. Progress in Haemostasis. From individual patients to pathophysiological insights. *Haemostaseologie* **2017**;37:9-11
103	Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, **Kremer Hovinga J**, Lämmle B, Matsumoto M, Pavenshi K, Sadler E, Sarode R, Wu H, on behalf of the international working group for Thrombotic thrombocytopenic purpura (TTP). Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. *J Thromb Haemost* **2017**;15:312-322
104	**Kremer Hovinga JA,** Coppo P. Lämmle B., Moake JL, Miyata T, Vanhoorelbeke K. Thrombotic thrombocytopenic purpura. *Nat Rev Dis Primers* **2017**;3:17020
105	Page EE, **Kremer Hovinga JA**, Terrell DR, Vesely SK, George JN. Thrombotic thrombocyto-penic purpura: Diagnostic criteria, presenting features, and long-term outcomes 1995-2015. *Blood Advances* **2017**;1:590-600
106	Peyvandi F, Scully M, **Kremer Hovinga JA**, Knöbl P, Cataland S, De Beuf K, Callewaert F, De Winter H, Zeldin RK. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. *J Thromb Haemost* **2017**;15:1448-1452
107	Ayanambakkam **A, Kremer Hovinga JA**, Vesely SK, George JN. Diagnosis of Thrombotic Thrombocytopenic Purpura among patients with ADAMTS13 activity 10-20%. *Am J Hematol* **2017**;92:E644-E646
108	Little DK, Mathias LM, Page EE, **Kremer Hovinga JA**, Vesely SK, George JN. Kidney Function in Patients with Acquired Thrombotic Thrombocytopenic Purpura: Initial Presentation and Long-Term Outcomes. A Prospective Analysis of Consecutive Patients. *Kidney International Reports* **2017**;2:1088-1095

109	Scully M**,** Knöbl P, Kentouche K, Rice L, Windyga J, Schneppenheim R, **Kremer Hovinga JA**, Kajiwara M, Fujimura Y, Maggiore C, Doralt J, Hibbard C, Martell L, Ewenstein B. Recombinant human ADAMTS-13: first-in-human study evaluating pharmacokinetics, safety and tolerability in cTTP patients. *BLOOD* **2017**;130:2055-2063
110	Prince R**,** Bologna L, Manetti M, Melchiorre D, Rosa I, Dewarrat N**,** Suardi S, Amini P, Fernández JA, Burnier L, Quarroz C**,** Reina Caro MD**,** Matsumura Y, **Kremer Hovinga JA**, Griffin JH, Simon HU, Ibba-Manneschi L, Saller F, Calzavarini S**,** Angelillo-Scherrer A**.** Targeting anticoagulant protein S to improve hemostasis in hemophilia. *BLOOD* **2018**;131: 1360-1371
111	**Kremer Hovinga JA**, Heeb SR, Skowronska M, Schaller M. Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. *J Thromb Haemostas* **2018**;16: 618-629
112 Not in pub med	Schmid M, Spichiger E, **Kremer Hovinga JA**. Aufbau einer interprofessionellen Betreuung für Patientinnen/Patienten mit angeborenen Hämostasestörungen (Development of an interprofessional care for patients with hereditary bleeding disorders). *Pflegewissenschaft* **2019**;3/4:110-117 *(*DOI: 10.3936/1588)
113	Scully M, Cataland S, Peyvandi F, Coppo P, Knöbl P, **Kremer Hovinga JA**, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK for the HERCULES Investigators. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. *N Engl J Med* **2019**;380:335-46
114	Van Dorland HA, Mansouri Taleghani M, Sakai K, Friedman KD, George JN, Hrachovinova I, Knöbl PN, von Krogh AS, Schneppenheim R, Aebi-Huber I, Bütikofer L, Largiadèr CR, Cermakova Z, Kokame K, Miyata T, Yagi H, Terrell DR, Vesely SK, Matsumoto M, Lämmle B, Fujimura Y, **Kremer Hovinga JA**. The International Hereditary Thrombotic Thrombocyto-penic Purpura Registry: Key findings at enrolment until 2017. *Haematologica* **2019**;104:2107-2115
115	Schneider C, Stutz-Grunder E, Lüer S, Keller P, **Kremer Hovinga JA**, Ammann RA, Karow A. Fulminant essential thrombocythemia associated with acquired von Willebrand syndrome and bleeding episodes in a 14-year-old girl. *Haemostaseologie* **2019**;39:404-408
116	Tiefenbacher S, Albisetti M, Baker P, Kappert G, Kitchen S, **Kremer Hovinga JA**, Poulard C, Scholz U, Ternisien C, Borgvall C, Vincente T, Belyanskaya L, Walter O, Oldenburg J on BEHALF OF THE NUWIQ FIELD STUDY PARTICIPATING LABORATORIES. Estimation of Nuwiq® (simoctocog alfa) activity using one-stage and chromogenic assays – results from an international comparative field study. *Haemophilia* **2019**;25:708–717
117	Robertz J, Andres M, Mansouri Taleghani B, **Kremer Hovinga JA**. Obinutuzumab in two patients suffering from immune-mediated thrombotic thrombocytopenic purpura intolerant to rituximab. *Am J Hematol* **2019**;94:E259-E261
118	Angelillo-Scherrer A, Mansouri Taleghani B, Förger F, Baerlocher GM, Pabst T, Pöllinger A, Banz Y, Geiser T, **Kremer Hovinga JA**, Rovó A. Immunoadsorption and autologous trans-plantation for life-threatening primary antiphospholipid syndrome. *Blood Adv* **2019**;3:2664-2667
119	**Kremer Hovinga JA**, George JN. Hereditary thrombotic thrombocytopenic purpura. *N Engl J Med* **2019**;381:1653-1662
120	Orosz ZZ; Bárdos H, Shemirani AH, Beke Debreceni I, Lassila R, Riikonen A, **Kremer Hovinga JA**, Seiler TG, van Dorland HA, Schroeder V, Boda Z, Nemes L, Nagy B, Facskó A, Kappelmayer J, Muszbek L. Cellular factor XIII, a transglutaminase in human corneal keratocytes. *Int J Mol Sci* **2019**;20(23):5963

121	**Kremer Hovinga JA**, George JN. Hereditary Thrombotic Thrombocytopenic Purpura. Reply. *N Engl J Med* **2020**;382:394
122	Knöbl P, Cataland S, Peyvandi F, Coppo P, Scully M, **Kremer Hovinga JA**, Metjian A, de la Rubia J, Pavenski K, Minkue Mi Edou J, De Winter H, Callewaert F. Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. *J Thromb Haemost* **2020**;18:479-484
123	Barco S, Sollfrank S, Trinchero A, Adenaeuer A, Abolghasemi H, Conti L, Häuser F, **Kremer Hovinga JA**, Lackner KJ, Loewecke F, Miloni E, Shiran NV, Tomao L, Wuillemin WA, Zieger B, Lämmle B, Rossmann H. Severe plasma prekallikrein deficiency: clinical characteristics, novel *KLKB1* mutations, and estimated prevalence. *J Thromb Haemost* **2020**;18:1598-1617
124	Casini A, Alberio L, Angelillo-Scherrer A, Fontana P, Gerber B, Graf L, Hegemann I, Korte W, **Kremer Hovinga J**, Lecompte T, Martinez M, Nagler M, Studt JD, Tsakiris D, Wuillemin W, Asmis L. Thromboprophylaxis and laboratory monitoring for in-hospital patients with COVID-19 - a Swiss consensus statement by the Working Party Hemostasis. *Swiss Med Wkly*. **2020**;150:w20247
125	Alberio L, Angelillo-Scherrer A, Asmis L, Casini A, Fontana P, Graf L, Hegemann I, **Kremer Hovinga JA**, Korte W, Lecompte T, Martinez M, Nagler M, Studt JD, Tsakiris DA, Wuillemin W. Recommendations on the use of anticoagulants for the treatment of patients with heparin-induced thrombocytopenia in Switzerland. *Swiss Med Wkly*. **2020**;150:w20210
126 Not in pub med	Borogovac A, Tarasco E, **Kremer Hovinga JA**, George JN. Hypertension in patients with hereditary thrombotic thrombocytopenic purpura. *eJHaem.* **2020**;1–2.
127	Mackie I, Mancini I, Muia J, **Kremer Hovinga J**, Nair S, Machin S, Baker R. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of ADAMTS13. *Int J Lab Hematol*. **2020**;42:685–696
128	Jalowiec K, Andres M; Mansouri Taleghani B, Musa A, Dickenmann M, Angelillo-Scherrer A, Rovó A, **Kremer Hovinga JA**. Acquired Hemophilia A and Plasma Cell Neoplasms, case report and literature review. *J Med Case Rep*. **2020**;14:206
129	**Kremer Hovinga JA**, Braschler TR, Buchkremer F, Farese S, Hengartner H, Lovey PY, Largiadèr CR, Mansouri Taleghani B, Tarasco E. Insights from the Hereditary Thrombotic Thrombocytopenic Purpura Registry: Discussion of Key Findings Based on Individual Cases from Switzerland. Haemostaseologie. 2020;40 (S 01):S5-S14.
130	Li A, **Kremer Hovinga JA**. Laboratory surveillance of immune-mediated thrombotic thrombocytopenic purpura. *Hematology Am Soc Hematol Educ Program*. **2020**;2020:82-84
131	Cuker A, Cataland SR, Coppo P, de la Rubia J, Friedman KD, George JN, Knoebl PN, **Kremer Hovinga JA**, Lämmle B, Matsumoto M, Pavenski K, Peyvandi F, Sakai K, Sarode R, Thomas MR, Tomiyama Y, Veyradier A, Westwood JP, Scully M for the International Working Group for Thrombotic Thrombocytopenic Purpura. Redefining Outcomes in Immune TTP: An International Working Group Consensus Report. *Blood* **2021**; in press

2.) Book chapters

1	**Kremer Hovinga JA**, Otten JMM, Levi MM, ten Cate H. Disease specific mechanisms of disseminated intravascular coagulation. In: ten Cate H, Levi M, eds. *Molecular Mechanisms of Disseminated Intravascular Coagulation*. Landes Biosciences, Georgetown, TX, United States **2001** (ISBN 1-58706-058-2).
2	Lämmle B, **Kremer Hovinga JA**. Thrombotisch thrombozytopenische Purpura, hämolytisch-urämisches Syndrom und andere thrombotische Mikroangiopathien. In *Pötzsch B (Hrsg.) Hämostaseologie: Grundlagen, Diagnostik und Therapie*. Springer, Heidelberg, Germany **2009**
3	**Kremer Hovinga JA**. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. In *Platelets in Thrombotic and Non-Thrombotic Disorders*. Gresele P, Kleiman NS, Lopez JA, Page CP (eds). Springer International Publishing AG **2017**, DOI 10.1007/978-3-319-47462-5; ISBN 978-3-319-47462-1 (e-book: ISBN 978-3-319-47462-5)
4	**Kremer Hovinga JA**. Thrombose und Thrombozytopenie. In *Haemostase-Update 2017: Hämophilie/Haemostaseologie 2017*. Lindhoff-Last E, Kemkes-Matthes B, Oldenburg J, Tiede A (eds). med publico GmbH; ISBN Print 978-3-86302-440-6 (ISBN ePub: 978-3-86302-440-3)
5	**Kremer Hovinga JA**. Thrombose und Thrombozytopenie. In *Haemostase-Update 2018: Hämophilie/Haemostaseologie 2018*. Lindhoff-Last E, Kemkes-Matthes B, Oldenburg J, Tiede A (eds). med publico GmbH; ISBN Print 978-3-86302-595-3 (ISBN ePub: 978-3-86302-595-0)

3.) Other publications

1	**Kremer Hovinga JA**°, Colucci G, Alberio L, Lämmle B. Wenn die Mikrozirkulation durch Plättchenklumpen verstopft wird - Die Folgen einer ungenügenden “Proteinschere”. *UNIPRESS (Forschung und Wissenschaft an der Universität Bern)* **2004**;123:19-21
2	Wikipedia Article on hereditary TTP (Upshaw-Schulman syndrome) – Master thesis of Ursula Schmutz (Medical faculty, University of Bern, **2015**) • https://de.wikipedia.org/wiki/Upshaw-Schulman-Syndrom (in German) • https://en.wikipedia.org/wiki/Upshaw%E2%80%93Schulman_syndrome (in English)
3	Tarasco E. Aebi-Huber I, **Kremer Hovinga JA**. Die erbliche Form der thrombotisch thrombozytopenischen Purpura (TTP) – selten, aber bei Schwangerschaftskomplikationen zu bedenken! *Vasomed* 2020;32(3):90-91
4	Tarasco E. Aebi-Huber I, **Kremer Hovinga JA**. The Hereditary TTP Registry: who we are, what we do, why you should join us. *Leading Opinions Hämatologie & Onkologie* 2020;3:6-8